---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-188851"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2023-07-18T23:59:59+00:00"
generated_at: "2026-06-13T07:16:53.095738+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# IO Biotech appoints Qasim Ahmad as CMO, promotes Eric Faulkner to CTO

## Summary
- Qasim Ahmad, MD, appointed CMO effective July 15; previously Novartis SVP, US Head Clinical Development & Medical Affairs.
- Eva Ehrnrooth transitions from CMO to Senior Clinical Advisor; departure not due to any disagreement.
- Eric Faulkner promoted to CTO; previously Sr. VP CMC, will oversee CMC and Quality for commercial readiness.
- Ahmad granted inducement option for 288,153 shares vesting over 4 years (25% cliff at year one).
- Changes position company for BLA filing and next stage of growth; Ahmad based in US.

## SEC filing metadata
- accession: 0001193125-23-188851
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2023-07-18T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312523188851/0001193125-23-188851-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312523188851/d523717d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-188851
- JSON: https://secwatch.observer/filing/0001193125-23-188851.json
- Plain text: https://secwatch.observer/filing/0001193125-23-188851.txt

## Key facts
- Executive change
  Qasim Ahmad was appointed as Chief Medical Officer at IO Biotech, Inc..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: On July 15, 2023, IO Biotech, Inc. (the “Company”) appointed Qasim Ahmad, M.D. as the Company’s Chief Medical Officer, effective as of that same date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312523188851/0001193125-23-188851-index.htm
- Executive change
  Eva Ehrnrooth changed role as Senior Clinical Advisor at IO Biotech, Inc..
  - Action: transition
  - Role: Senior Clinical Advisor
  source text: Dr. Ehrnrooth will now transition from her role as Chief Medical Officer to Senior Clinical Advisor, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312523188851/0001193125-23-188851-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.